Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia
出版年份 2017 全文链接
标题
Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia
作者
关键词
-
出版物
Expert Review of Clinical Pharmacology
Volume 10, Issue 2, Pages 131-151
出版商
Informa UK Limited
发表日期
2016-12-22
DOI
10.1080/17512433.2017.1275570
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade
- (2016) E C Alexandre et al. BRITISH JOURNAL OF PHARMACOLOGY
- Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics
- (2016) Adrian Wagg et al. CURRENT MEDICAL RESEARCH AND OPINION
- Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome
- (2016) Gian Marco Rosa et al. EUROPEAN UROLOGY
- Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)
- (2016) Marcus J. Drake et al. EUROPEAN UROLOGY
- Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy
- (2016) Scott MacDiarmid et al. JOURNAL OF UROLOGY
- β3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project
- (2016) Martin C. Michel et al. PHARMACOLOGY & THERAPEUTICS
- A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron
- (2015) Kirill Kosilov et al. ARCHIVES OF GERONTOLOGY AND GERIATRICS
- Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study)
- (2015) Osamu Yamaguchi et al. BJU INTERNATIONAL
- Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects
- (2015) Hiromi Iitsuka et al. CLINICAL THERAPEUTICS
- Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada
- (2015) Adrian Wagg et al. CUAJ-Canadian Urological Association Journal
- Involvement of β3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: Direct evidence by [3H]-acetylcholine release experiments in the isolated detrusor
- (2015) Gianluigi D׳Agostino et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Efficacy of the β3-adrenoceptor Agonist Mirabegron for the Treatment of Overactive Bladder by Severity of Incontinence at Baseline: A Post Hoc Analysis of Pooled Data from Three Randomised Phase 3 Trials
- (2015) Christopher Chapple et al. EUROPEAN UROLOGY
- Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)
- (2015) Paul Abrams et al. EUROPEAN UROLOGY
- A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction
- (2015) Koji Ichihara et al. JOURNAL OF UROLOGY
- The characteristics of intrinsic complex micro-contractile activity in isolated strips of the rat bladder
- (2015) J. I. Gillespie et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- The expression of β3-adrenoceptor and muscarinic type 3 receptor immuno-reactivity in the major pelvic ganglion of the rat
- (2015) J. Eastham et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- The actions of prolonged exposure to cholinergic agonists on isolated bladder strips from the rat
- (2015) James I. Gillespie et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Beta adrenergic modulation of spontaneous microcontractions and electrical field-stimulated contractions in isolated strips of rat urinary bladder from normal animals and animals with partial bladder outflow obstruction
- (2015) J .I. Gillespie et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Prostaglandin E2 excitatory effects on rat urinary bladder: a comparison between the β-adrenoceptor modulation of non-voiding activity in vivo and micro-contractile activity in vitro
- (2015) C. Granato et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Patient-reported outcomes with the β3-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder
- (2015) Vik Khullar et al. NEUROUROLOGY AND URODYNAMICS
- The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials
- (2015) D. Castro-Diaz et al. QUALITY OF LIFE RESEARCH
- Tissue-based map of the human proteome
- (2015) M. Uhlen et al. SCIENCE
- Urodynamic Evaluation of the Efficacy of Mirabegron on Storage and Voiding Functions in Women With Overactive Bladder
- (2015) Yoshihisa Matsukawa et al. UROLOGY
- Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Japanese Patients with Overactive Bladder
- (2015) Osamu YAMAGUCHI et al. LUTS-Lower Urinary Tract Symptoms
- The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients
- (2014) Adrian Wagg et al. AGE AND AGEING
- Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder
- (2014) Osamu Yamaguchi et al. BJU INTERNATIONAL
- Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence
- (2014) Emilio Sacco et al. Expert Opinion on Drug Discovery
- Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men
- (2014) Marcel van Gelderen et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Comorbidities and personal burden of urgency urinary incontinence: a systematic review
- (2014) K. S. Coyne et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Safety and tolerability of the β3-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial
- (2014) V. W. Nitti et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia
- (2014) Hann-Chorng Kuo et al. NEUROUROLOGY AND URODYNAMICS
- Effects ofL-arginine, mirabegron, and oxybutynin on the primary bladder afferent nerve activities synchronized with reflexic, rhythmic bladder contractions in the rat
- (2014) Naoki Aizawa et al. NEUROUROLOGY AND URODYNAMICS
- Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013
- (2014) Marcus J. Drake NEUROUROLOGY AND URODYNAMICS
- Do Patient Characteristics Predict Responsiveness to Treatment of Overactive Bladder With Antimuscarinic Agents?
- (2014) Sender Herschorn et al. UROLOGY
- Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
- (2014) Christopher R. Chapple et al. WORLD JOURNAL OF UROLOGY
- Efficacy and Safety of the Selective β3-Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study
- (2014) Osamu YAMAGUCHI et al. LUTS-Lower Urinary Tract Symptoms
- Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy Japanese Male Subjects: Results from Single- and Multiple-Dose Studies
- (2013) Hiromi Iitsuka et al. CLINICAL DRUG INVESTIGATION
- Role of Cytochrome P450 Isoenzymes 3A and 2D6 in the In Vivo Metabolism of Mirabegron, a β3-Adrenoceptor Agonist
- (2013) Jennifer Lee et al. CLINICAL DRUG INVESTIGATION
- The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol
- (2013) Walter Krauwinkel et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Protective Effect of a β3-Adrenoceptor Agonist on Bladder Function in a Rat Model of Chronic Bladder Ischemia
- (2013) Norifumi Sawada et al. EUROPEAN UROLOGY
- Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison
- (2013) Khaled Maman et al. EUROPEAN UROLOGY
- The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option
- (2013) Mahendra Kashyap et al. Expert Opinion on Drug Metabolism & Toxicology
- Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
- (2013) V. W. Nitti et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis
- (2013) Antoni Sicras-Mainar et al. INTERNATIONAL UROGYNECOLOGY JOURNAL
- A phase II dose-ranging study of mirabegron in patients with overactive bladder
- (2013) Christopher R. Chapple et al. INTERNATIONAL UROGYNECOLOGY JOURNAL
- Randomized, Double-Masked, Placebo-Controlled Study to Assess the Ocular Safety of Mirabegron in Healthy Volunteers
- (2013) Gary D. Novack et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Urodynamics and Safety of the β3-Adrenoceptor Agonist Mirabegron in Males with Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
- (2013) Victor W. Nitti et al. JOURNAL OF UROLOGY
- Long-Term Adherence to Antimuscarinic Therapy in Everyday Practice: A Systematic Review
- (2013) Paul W. Veenboer et al. JOURNAL OF UROLOGY
- In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats
- (2013) Toshiki Hatanaka et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats
- (2013) Toshiki Hatanaka et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- β3-Adrenoceptors: a drug target in ophthalmology?
- (2013) Adrian Gericke et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys
- (2013) Toshiki Hatanaka et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- A proof-of-concept study: Mirabegron, a new therapy for overactive bladder
- (2013) Christopher R. Chapple et al. NEUROUROLOGY AND URODYNAMICS
- Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability
- (2013) Christopher R. Chapple et al. NEUROUROLOGY AND URODYNAMICS
- A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder
- (2013) Sender Herschorn et al. UROLOGY
- Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial
- (2013) Vik Khullar et al. BMC Urology
- Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience
- (2012) Adrian Wagg et al. BJU INTERNATIONAL
- Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β3-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction
- (2012) James I. Gillespie et al. BJU INTERNATIONAL
- Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study
- (2012) M Malik et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Effects of Mirabegron, a Novel β3-Adrenoceptor Agonist, on Primary Bladder Afferent Activity and Bladder Microcontractions in Rats Compared With the Effects of Oxybutynin
- (2012) Naoki Aizawa et al. EUROPEAN UROLOGY
- Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder
- (2012) Christopher R. Chapple et al. EUROPEAN UROLOGY
- Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial
- (2012) Vik Khullar et al. EUROPEAN UROLOGY
- β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men
- (2012) Hideo Otsuki et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder
- (2012) Victor W. Nitti et al. JOURNAL OF UROLOGY
- Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction
- (2011) Debra E. Irwin et al. BJU INTERNATIONAL
- Pathophysiology of the lower urinary tract and CNS
- (2011) Christopher Chapple CUAJ-Canadian Urological Association Journal
- Comparative adherence to oxybutynin or tolterodine among older patients
- (2011) Tara Gomes et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature
- (2011) C. C. Sexton et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement?
- (2010) Linda Cardozo et al. BJU INTERNATIONAL
- Are there functional β3-adrenoceptors in the human heart?
- (2010) Martin C Michel et al. BRITISH JOURNAL OF PHARMACOLOGY
- Low persistence of anticholinergic drug use in Sweden
- (2010) Love Linnér et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS
- (2009) Chris C. Sexton et al. BJU INTERNATIONAL
- Patient-reported reasons for discontinuing overactive bladder medication
- (2009) Joshua S. Benner et al. BJU INTERNATIONAL
- A review of adherence to drug therapy in patients with overactive bladder
- (2008) Ramandeep K. Basra et al. BJU INTERNATIONAL
- The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis
- (2008) Christopher R. Chapple et al. EUROPEAN UROLOGY
- Unknown
- (2008) L. A. Leon et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Catecholamines Relax Detrusor through 2-Adrenoceptors in Mouse and 3-Adrenoceptors in Man
- (2008) M. Wuest et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Expression and functional role of β-adrenoceptors in the human urinary bladder urothelium
- (2008) Atsushi Otsuka et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started